

1/15





Fig. 1

2/15



N.meningitidis LPS

Fig. 2

3/15




Fig. 3

4/15




Fig. 4

5/15







Fig. 5

6/15




Fig. 6

7/15




Fig. 7

8/15




Fig. 8

9/15

STRATEGY DIAGRAM
(Methods used in brackets)

↓
Identify antibody
accessible epitopes of
wild-type encapsulated
Gp B Nm strains
(2,3,4)

↓
Investigate conservation
of antibody accessible
inner core epitopes in
natural population of Nm
(3)

↓
Investigate the structure
of LPS derived from Nm
of known mab reactivity
(5)

↓
Define details of
conserved antibody
accessible epitopes
(2,5)

↓
Select minimum number
of glycoforms having
range of epitopes
representative of all Nm
strains
(3,4,5)

↓
Investigate potential of
glycoform to elicit
functional antibodies
(e.g bacterial,
opsonophagocytic &
animal protection
assays)

Fig. 9

10/15




Fig. 10a





Fig. 10b



B5+ galE LPS
B5- galE LPS

Fig. 11a




Fig. 11b




Fig. 11c

12/15




Fig. 12

13/15





Fig. 13

14/15



MC58

L3 *galE*

Fig. 14

15/15




Fig. 15